Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases.

Trial Profile

Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Brain cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2015 As per NCT Primary end point was changed from "prevention of new brain metastases" to "Percentage of Participants With Distant Brain Failure (DBF) at One Year"
    • 17 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 25 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrial.gov record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top